Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprised of ABT-806, a mAB against EGFR, and a cytotoxic payload (monomethyl auristatin F). ABT-414 therapy initially showed promising results as an EGFRvIII therapy in vivo and in vitro; however, ABT414 failed to provide a...
Failed trials involving targeted therapies face a daunting task of understanding whether the root cause was inadequate targeting, resistance, or insufficient delivery to the tumor. Previous work with a bio-mathematical model has shown the prognostic value of an imaging based invasion metric, D/ρ (...